
Michela Buglione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5021819/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer. Tumori, 2022, 108, 470-476.	1.1	2
2	RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers, 2022, 14, 2273.	3.7	1
3	Clinical and pathological prognostic factors in Merkel cell carcinoma Journal of Clinical Oncology, 2022, 40, e21574-e21574.	1.6	Ο
4	Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiologia Medica, 2021, 126, 142-146.	7.7	27
5	Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group. World Journal of Urology, 2021, 39, 1161-1170.	2.2	4
6	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
7	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiotherapy and Oncology, 2021, 155, 120-122.	0.6	5
8	Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1773-1779.	2.5	5
9	Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2021, 147, 793-802.	2.5	Ο
10	Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study. Cancers, 2021, 13, 1479.	3.7	5
11	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncology, 2021, 115, 105213.	1.5	33
12	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. Cancers, 2021, 13, 1791.	3.7	21
13	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. Cancers, 2021, 13, 2527.	3.7	17
14	A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin's Lymphoma. Critical Reviews in Oncology/Hematology, 2021, 167, 103437.	4.4	9
15	Universal testing for COVID-19 in patients undergoing cancer treatment during the second outbreak in Brescia. Tumori, 2021, , 030089162110349.	1.1	2
16	Advanced Radiotherapy Techniques for Mediastinal Lymphomas: Results from an Italian Survey. Hemato, 2021, 2, 496-504.	0.6	2
17	â€~Le Roi est mort, vive le Roi': new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	5
18	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Advances, 2021, 5, 4504-4514.	5.2	14

#	Article	IF	CITATIONS
19	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. European Journal of Cancer, 2021, 159, 194-204.	2.8	13
20	Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients. Radiation Oncology, 2021, 16, 239.	2.7	4
21	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. Tumori, 2020, 106, 177-189.	1.1	1
22	The linguistic validation process of the Vanderbilt Head and Neck Symptom Survey - Italian Version (VHNSS-IT). Radiologia Medica, 2020, 125, 228-235.	7.7	5
23	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative―intent. Lung Cancer, 2020, 141, 1-8.	2.0	17
24	Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable― Radiotherapy and Oncology, 2020, 150, 172-173.	0.6	2
25	Two months of radiation oncology in the heart of Italian "red zone―during COVID-19 pandemic: paving a safe path over thin ice. Radiation Oncology, 2020, 15, 191.	2.7	9
26	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	3.3	27
27	Letter to "Medial lingual lymph node metastasis in carcinoma of the tongue― Auris Nasus Larynx, 2020, 47, 1091-1092.	1.2	1
28	In reply to Simcock et al Clinical and Translational Radiation Oncology, 2020, 23, 65.	1.7	1
29	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiotherapy and Oncology, 2020, 149, 89-93.	0.6	43
30	A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes. Laboratory Investigation, 2020, 100, 1330-1344.	3.7	12
31	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. Clinical Lung Cancer, 2020, 21, e547-e550.	2.6	13
32	Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 469-477.	0.8	17
33	Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiation Oncology, 2020, 15, 62.	2.7	20
34	A pilot study on the Vanderbilt head and neck symptom survey Italian version (VHNSS-IT) to test its feasibility and utility in routine clinical practice. Radiologia Medica, 2020, 125, 423-431.	7.7	4
35	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.6	9
36	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE, 2019, 14, e0224151.	2.5	8

#	Article	IF	CITATIONS
37	Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers, 2019, 11, 1284.	3.7	90
38	Cetuximab and Radiation Therapy in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 678-679.	0.8	2
39	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. Journal of Neuro-Oncology, 2019, 143, 447-455.	2.9	6
40	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	2.2	69
41	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq1 1 0.784	4 3.1 34 rgBT	/ 2 verlock 1
42	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 C Reviews in Oncology/Hematology, 2019, 134, 104-119.) rgBT /Ove 4.4	erlock 10 Tf 10
43	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322.	7.7	11
44	Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells. Biochemical and Biophysical Research Communications, 2019, 508, 31-36.	2.1	5
45	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 0 Reviews in Oncology/Hematology, 2019, 134, 87-103.	.784314 rg 4.4	gBT /Overloo 7
46	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. Journal of Neurosurgical Sciences, 2019, 63, 458-467.	0.6	22
47	Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further. Radiologia Medica, 2018, 123, 63-70.	7.7	13
48	Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiologia Medica, 2018, 123, 48-62.	7.7	20
49	Reply to â€ ⁻ Comment on â€ ⁻ Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''. British Journal of Cancer, 2018, 118, e2-e2.	6.4	0
50	Correlation between Human Papillomavirus Status and Quantitative MR Imaging Parameters including Diffusion-Weighted Imaging and Texture Features in Oropharyngeal Carcinoma. American Journal of Neuroradiology, 2018, 39, 1878-1883.	2.4	39
51	Light and shadows of a new technique: isÂphoton total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?. Radiation Oncology, 2018, 13, 158.	2.7	11
52	Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists. Tumori, 2018, 104, 466-470.	1.1	0
53	Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An <i>In Vitro</i> Study. Anticancer Research, 2018, 38, 3487-3492.	1.1	8
54	Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. Tumori, 2018, 104, 394-400.	1.1	3

#	Article	IF	CITATIONS
55	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. In Vivo, 2018, 32, 159-164.	1.3	14
56	The growing role of biology in the treatment of glioblastoma: no more one kind of disease. Journal of Neuro-Oncology, 2017, 133, 211-212.	2.9	0
57	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. British Journal of Cancer, 2017, 116, 1520-1525.	6.4	121
58	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Critical Reviews in Oncology/Hematology, 2017, 117, 48-56.	4.4	12
59	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	10.7	15
60	Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 462-472.	0.8	35
61	A Neuro-Oncologic Challenge: The Case of a Large, Aggressive, Malignant Meningioma of the Skull Base with Paranasal Sinus Involvement. Tumori, 2016, 102, S5-S8.	1.1	2
62	Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?. Journal of Neuro-Oncology, 2016, 128, 303-312.	2.9	21
63	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	1.3	2
64	In reply to Borras et al. The strengthening of Radiation Oncologist role inside multidisciplinary arena within 2025. Radiotherapy and Oncology, 2016, 119, 369.	0.6	0
65	Post-ABVD/pre-radiotherapy ¹⁸ F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. British Journal of Radiology, 2016, 89, 20150983.	2.2	12
66	Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. British Journal of Radiology, 2016, 89, 20150981.	2.2	27
67	Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy. Radiologia Medica, 2016, 121, 696-703.	7.7	4
68	From Molecular to Clinical Radiation Biology of Glioblastoma. Current Clinical Pathology, 2016, , 275-292.	0.0	0
69	The "Radioresistance―of Clioblastoma in the Clinical Setting, and the Present Therapeutic Options. Current Clinical Pathology, 2016, , 15-27.	0.0	0
70	Radiation Tolerance of Normal Brain: QUANTEC 2010 and Beyond. Current Clinical Pathology, 2016, , 121-135.	0.0	1
71	Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique. Radiation Oncology, 2016, 11, 59.	2.7	15
72	Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology, 2016, 34, 427-435.	1.6	203

#	Article	IF	CITATIONS
73	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	4.4	51
74	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	4.4	112
75	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	4.4	82
76	Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV disease. Radiologia Medica, 2016, 121, 70-79.	7.7	8
77	Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature. Anticancer Research, 2016, 36, 2975-81.	1.1	8
78	Reirradiation in Head and Neck Recurrent or Second Primary Tumor: Efficacy, Safety, and Prognostic Factors. Tumori, 2015, 101, 585-592.	1.1	22
79	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 95, 191-213.	4.4	33
80	Optimizing Radiation Treatment Decisions for Patients Who Receive Neoadjuvant Chemotherapy. Journal of the National Cancer Institute Monographs, 2015, 2015, 9-10.	2.1	1
81	Could Concomitant Radio-Chemotherapy Improve the Outcomes of Early-Stage Node Negative Anal Canal Cancer Patients? A Retrospective Analysis of 122 Patients. Cancer Investigation, 2015, 33, 114-120.	1.3	10
82	EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide. Journal of the National Cancer Institute, 2015, 107, .	6.3	39
83	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.8	28
84	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 167-182.	4.4	46
85	The treatment of patients with 1–3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis. Radiologia Medica, 2015, 120, 1146-1152.	7.7	8
86	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 372-384.	4.4	95
87	Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Reports of Practical Oncology and Radiotherapy, 2015, 20, 284-291.	0.6	16
88	Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial― resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group. Radiologia Medica, 2015, 120, 975-981.	7.7	1
89	Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage I and II disease. Radiologia Medica, 2015, 120, 1071-1077.	7.7	6
90	Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Practical Radiation Oncology, 2015, 5, 383-389.	2.1	13

#	Article	IF	CITATIONS
91	Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic and Predictive Significance. PLoS ONE, 2014, 9, e103918.	2.5	69
92	External Beam Radiotherapy ± Chemotherapy in the Treatment of Anal Canal Cancer: A Single-Institute Long-Term Experience on 100 Patients. Cancer Investigation, 2014, 32, 248-255.	1.3	6
93	Surgery in cerebral metastases: Are numbers so important?. Journal of Cancer Research and Therapeutics, 2014, 10, 79.	0.9	28
94	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	1.6	6
95	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	4.4	25
96	Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis. Radiologia Medica, 2014, 119, 432-439.	7.7	11
97	The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications. Reports of Practical Oncology and Radiotherapy, 2014, 19, 77-91.	0.6	20
98	Changes in Patterns of Practice for Prostate Cancer Radiotherapy in Italy 1995–2003. A Survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-37.	1.1	7
99	Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-7.	1.1	6
100	Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. Tumori, 2014, 100, 272-7.	1.1	8
101	Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature. Journal of Medical Case Reports, 2013, 7, 64.	0.8	9
102	Predictive factors for oropharyngeal mycosis during radiochemotherapy for head and neck carcinoma and consequences on treatment duration. Results of mycosis in radiotherapy (MIR): A prospective longitudinal study. Radiotherapy and Oncology, 2013, 109, 303-310.	0.6	5
103	The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. Medical Oncology, 2013, 30, 729.	2.5	15
104	Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro-Oncology, 2013, 15, 618-625.	1.2	64
105	Exploiting Machine Learning for Predicting Nodal Status in Prostate Cancer Patients. IFIP Advances in Information and Communication Technology, 2013, , 61-70.	0.7	2
106	Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-Oncology, 2012, 14, 798-807.	1.2	26
107	Circulating Tumour Cells in locally advanced head and neck cancer: Preliminary report about their possible role in predicting response to non-surgical treatment and survival. European Journal of Cancer, 2012, 48, 3019-3026.	2.8	92
108	Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiotherapy and Oncology, 2011, 99, 356-361.	0.6	83

#	Article	IF	CITATIONS
109	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. Neurosurgery, 2010, 67, 446-458.	1.1	73
110	HERâ€2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinicoâ€pathologic study. Journal of Cellular and Molecular Medicine, 2009, 13, 3826-3833.	3.6	44
111	Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literature. Journal of Medical Case Reports, 2008, 2, 320.	0.8	22
112	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. International Journal of Radiation Oncology Biology Physics, 2006, 65, 788-799.	0.8	23
113	Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1387-1394.	0.8	88
114	Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1NO disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1378-1386.	0.8	114